Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

A new treatment combination for patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients.     Some background Chronic lymphocytic leukemia...

Read More

What are the real-world outcomes for ASCT-ineligible patients with refractory or relapsed HL who are given brentuximab vedotin?

Posted by on Feb 5, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...

Read More

A review of CAR-T cell therapy for CLL

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...

Read More

Current treatment options for patients with relapsed or difficult to treat mantle cell lymphoma

Posted by on Dec 4, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review explores the current treatments for patients with relapsed or difficult to treat mantle cell lymphoma.  Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma. Patients with relapsed MCL generally have poor outcomes. These patients with relapsed or difficult to treat (refractory) MCL have...

Read More

A review of venetoclax for previously treated CLL

Posted by on Dec 2, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Lenalidomide treatment for patients with relapsed diffuse large B-cell lymphoma

Posted by on Oct 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...

Read More